{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:19:08Z","timestamp":1778566748161,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014361","name":"Hubei University of Medicine","doi-asserted-by":"publisher","award":["XYY2023D05"],"award-info":[{"award-number":["XYY2023D05"]}],"id":[{"id":"10.13039\/501100014361","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012554","name":"Hubei Provincial Department of Education","doi-asserted-by":"publisher","award":["XYY2023ZY01"],"award-info":[{"award-number":["XYY2023ZY01"]}],"id":[{"id":"10.13039\/100012554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Xiangyang No.1 People's Hospital","award":["D20232101"],"award-info":[{"award-number":["D20232101"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jad.2025.119481","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T18:33:52Z","timestamp":1748111632000},"page":"119481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Investigation into neuroleptic malignant syndrome triggered by atypical antipsychotics: Insights from FDA adverse event reporting system database"],"prefix":"10.1016","volume":"386","author":[{"given":"Jinhao","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuehu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2025.119481_bb0005","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4088\/JCP.v65n0403","article-title":"Neuroleptic malignant syndrome and atypical antipsychotic drugs","volume":"65","author":"Ananth","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2025.119481_bb0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/pcn.12793","article-title":"Adverse reaction reports of neuroleptic malignant syndrome induced by atypical antipsychotic agents in the Japanese adverse drug event report (JADER) database","volume":"73","author":"Anzai","year":"2019","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2025.119481_bb0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.schres.2014.01.030","article-title":"Genetic modifiers and subtypes in schizophrenia: investigations of age at onset, severity, sex and family history","volume":"154","author":"Bergen","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jad.2025.119481_bb0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/1941875210386491","article-title":"Neuroleptic malignant syndrome","volume":"1","author":"Berman","year":"2011","journal-title":"Neurohospitalist"},{"key":"10.1016\/j.jad.2025.119481_bb0025","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2165\/11599740-000000000-00000","article-title":"A signal detection method to detect adverse drug reactions using a parametric time-to-event model in simulated cohort data","volume":"35","author":"Cornelius","year":"2012","journal-title":"Drug Saf."},{"key":"10.1016\/j.jad.2025.119481_bb0030","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2165\/11599740-000000000-00000","article-title":"A signal detection method to detect adverse drug reactions using a parametric time-to-event model in simulated cohort data","volume":"35","author":"Cornelius","year":"2012","journal-title":"Drug Saf."},{"key":"10.1016\/j.jad.2025.119481_bb0035","article-title":"The broad spectrum of malignant syndromes","volume":"106734","author":"Cuccarelli","year":"2024","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jad.2025.119481_bb0040","first-page":"111","article-title":"Electroconvulsive therapy in the treatment of the neuroleptic malignant syndrome","volume":"7","author":"Davis","year":"1991","journal-title":"Convuls. Ther."},{"key":"10.1016\/j.jad.2025.119481_bb0045","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.psym.2012.06.011","article-title":"Atypical neuroleptic malignant syndrome associated with Iloperidone administration","volume":"53","author":"Guanci","year":"2012","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jad.2025.119481_bb0050","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/acps.12694","article-title":"A systematic review of sex and age factors in neuroleptic malignant syndrome diagnosis frequency","volume":"135","author":"Gurrera","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2025.119481_bb0055","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1212\/WNL.31.2.132","article-title":"Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade?","volume":"31","author":"Henderson","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/j.jad.2025.119481_bb0060","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/JCP.0000000000001019","article-title":"Low incidence of neuroleptic malignant syndrome associated with Paliperidone palmitate long-acting injectable","volume":"39","author":"Kane","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.119481_bb0065","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/acps.13215","article-title":"The neuroleptic malignant syndrome\u2014a systematic case series analysis focusing on therapy regimes and outcome","volume":"142","author":"Kuhlwilm","year":"2020","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2025.119481_bb0070","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/JCP.0000000000000774","article-title":"Lurasidone-associated neuroleptic malignant syndrome","volume":"37","author":"Lee","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.119481_bb0075","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2288-14-17","article-title":"Estimating time-to-onset of adverse drug reactions from spontaneous reporting databases","volume":"14","author":"Leroy","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.jad.2025.119481_bb0080","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/cpt.3139","article-title":"Drug-induced acute pancreatitis: a real-world pharmacovigilance study using the FDA adverse event reporting system database","volume":"115","author":"Li","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jad.2025.119481_bb0085","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/cpt.3098","article-title":"Postmarketing safety of Sacituzumab Govitecan: a pharmacovigilance study based on the FDA adverse event reporting system","volume":"115","author":"Li","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jad.2025.119481_bb0090","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/14740338.2023.2243220","article-title":"Gender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system","volume":"23","author":"Li","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jad.2025.119481_bb0095","doi-asserted-by":"crossref","first-page":"23","DOI":"10.9740\/mhc.2024.02.023","article-title":"Serotonin syndrome and neuroleptic malignant syndrome: a case report of intersecting symptomatology","volume":"14","author":"Maktabi","year":"2024","journal-title":"Ment Health Clin"},{"key":"10.1016\/j.jad.2025.119481_bb0100","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3928\/0048-5713-20000501-14","article-title":"Central dopamine Hypoactivity and the pathogenesis of neuroleptic malignant syndrome","volume":"30","author":"Mann","year":"2000","journal-title":"Psychiatr. Ann."},{"key":"10.1016\/j.jad.2025.119481_bb0105","doi-asserted-by":"crossref","first-page":"427","DOI":"10.4088\/JCP.10m06791","article-title":"Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs","volume":"73","author":"Nakamura","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2025.119481_bb0110","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.2147\/DDDT.S81998","article-title":"Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases","volume":"9","author":"Nomura","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.jad.2025.119481_bb0115","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/NDT.S118438","article-title":"Neuroleptic malignant syndrome: an easily overlooked neurologic emergency","volume":"13","author":"Oruch","year":"2017","journal-title":"NDT"},{"key":"10.1016\/j.jad.2025.119481_bb0120","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/JCP.0000000000001781","article-title":"Neuroleptic malignant syndrome associated with Lurasidone","volume":"43","author":"P\u00e0mpols-P\u00e9rez","year":"2023","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.119481_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.113583","article-title":"A case of extended-release quetiapine causing recurrent low-grade fevers","volume":"295","author":"Puthran","year":"2021","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2025.119481_bb0130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00406-018-0959-2","article-title":"Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993\u20132015","volume":"270","author":"Schneider","year":"2020","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2025.119481_bb0135","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1176\/ajp.2007.164.6.870","article-title":"Neuroleptic malignant syndrome","volume":"164","author":"Strawn","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.119481_bb0140","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s12603-014-0464-x","article-title":"Influence of age and gender on fat mass, fat-free mass and skeletal muscle mass among Australian adults: the Australian diabetes, obesity and lifestyle study (AusDiab)","volume":"18","author":"Strugnell","year":"2014","journal-title":"The Journal of nutrition, health and aging"},{"key":"10.1016\/j.jad.2025.119481_bb0145","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-024-03227-5","article-title":"Neuroleptic malignant syndrome and serotonin syndrome: a comparative bibliometric analysis","volume":"19","author":"Sweileh","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.jad.2025.119481_bb0150","series-title":"Handbook of clinical neurology, thermoregulation: from basic neuroscience to clinical neurology, Part II","first-page":"663","article-title":"Chapter 39 - neuroleptic malignant syndrome and serotonin syndrome","author":"Tormoehlen","year":"2018"},{"key":"10.1016\/j.jad.2025.119481_bb0155","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40264-016-0499-5","article-title":"Identification of substandard medicines via disproportionality analysis of individual case safety reports","volume":"40","author":"Trippe","year":"2017","journal-title":"Drug Saf."},{"key":"10.1016\/j.jad.2025.119481_bb0160","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1192\/bjp.bp.111.105189","article-title":"Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics","volume":"201","author":"Trollor","year":"2012","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.119481_bb0165","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2174\/1570159X13999150424113345","article-title":"Neuroleptic malignant syndrome: a review from a clinically oriented perspective","volume":"13","author":"Tse","year":"2015","journal-title":"CN"},{"key":"10.1016\/j.jad.2025.119481_bb0170","first-page":"1143","article-title":"Efficacy of prolonged large-dose Dantrolene for severe neuroleptic malignant syndrome","volume":"86","author":"Tsujimoto","year":"1998","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.jad.2025.119481_bb0175","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ajp.2017.05.004","article-title":"Neuroleptic malignant syndrome: a neuro-psychiatric emergency: recognition, prevention, and management","volume":"29","author":"Velamoor","year":"2017","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.jad.2025.119481_bb0180","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: a novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med. Decis. Mak."},{"key":"10.1016\/j.jad.2025.119481_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1094356","article-title":"Mitochondrial calcium cycling in neuronal function and neurodegeneration","volume":"11","author":"Walters","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.jad.2025.119481_bb0190","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1056\/NEJMra2404606","article-title":"Neuroleptic Malignant Syndrome","volume":"391","author":"Wijdicks","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2025.119481_bb0195","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1007\/s00431-023-05146-2","article-title":"Drug-associated kidney injury in children: a disproportionality analysis of the FDA adverse event reporting system","volume":"182","author":"Zhang","year":"2023","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.jad.2025.119481_bb0200","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s40264-016-0503-0","article-title":"Signal detection based on time to onset algorithm in spontaneous reporting system of China","volume":"40","author":"Zhang","year":"2017","journal-title":"Drug Saf."},{"key":"10.1016\/j.jad.2025.119481_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1338902","article-title":"Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database","volume":"15","author":"Zou","year":"2024","journal-title":"Front. Pharmacol."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725009231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725009231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:57:46Z","timestamp":1778565466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032725009231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":41,"alternative-id":["S0165032725009231"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.119481","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigation into neuroleptic malignant syndrome triggered by atypical antipsychotics: Insights from FDA adverse event reporting system database","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.119481","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119481"}}